Form 4: Edwards Lifesciences CEO Executes Planned Stock Sale

CEO Bernard J. Zovighian sold 523 shares of Edwards Lifesciences common stock via a pre-arranged Rule 10b5-1 trading plan.

Summary

• CEO Bernard J. Zovighian sold 523 shares of common stock at a price of $87.92 per share.
• The transaction was executed on June 17, 2026.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on December 12, 2025.
• Following the transaction, the CEO retains direct ownership of 99,164.6499 shares and indirect ownership of 11,516.5511 shares via a trust and 3,733.5603 shares via a 401(k).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-existing, automated trading plan.

Positives

• The transaction was pre-planned, indicating the sale was not based on non-public information or immediate market sentiment.

Negatives

• Insider selling, even when pre-planned, reduces the executive's direct equity stake in the company.

Risks

• Continued reliance on Rule 10b5-1 plans for liquidity may signal ongoing divestment by key leadership.

Future Outlook

No specific forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for executives to manage personal liquidity and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard regulatory compliance mechanism for corporate executives across the medical device industry, including peers like Medtronic and Boston Scientific.

Stakeholder Impact

• Minimal impact on shareholders as the sale represents a very small fraction of the CEO's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Edwards Lifesciences, EW, Insider Trading, Form 4, CEO, Stock Sale